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ABSTRACT 
Background The lack of reliable biomarkers to track disease progression is a major 
problem in clinical research of chronic neurological disorders. Using Huntington’s 
disease (HD) as an example, we describe a novel approach to model HD and show that 
the progression of a neurological disorder can be predicted for individual patients.  
Methods Starting with an initial cohort of 343 HD patients that we have followed since 
1995, we used data from 68 patients that satisfied our filtering criteria to model disease 
progression, based on the Unified Huntington's Disease Rating Scale (UHDRS), a 
measure that is routinely used in HD clinics worldwide.  
Results Our model was validated using: a) extrapolating our equation to model the age of 
disease onset, b) testing it on a second patient dataset by loosening our filtering criteria, 
c) cross-validating with a repeated random sub-sampling approach, and d) holdout 
validating with the latest clinical assessment data from the same cohort of patients. With 
UHDRS scores from the past four clinical visits (over a minimum span of two years), our 
model predicts disease progression of individual patients over the next two years with an 
accuracy of 89-91%. We have also provided evidence that patients with similar baseline 
clinical profiles can exhibit very different trajectories of disease progression.  
Conclusion This new model therefore has important implications for HD research, most 
obviously in the development of potential disease-modifying therapies. We believe that 
similar approach can also be adapted to model disease progression in other chronic 
neurological disorders. 
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INTRODUCTION 
The lack of reliable biomarkers to track disease progression is a major problem in clinical 
research of chronic neurological disorders.
1
 This problem has gained prominence as the 
development of disease-modifying therapies starts to enter the clinic,
2
 especially as some 
of these novel therapeutic agents or therapies involve direct delivery into the brain, and as 
such randomised controlled trials (RCT) are not always possible.
3
 Furthermore RCTs in 
neurological disorders with a low prevalence, such as Huntington’s disease (HD), can be 
further complicated by virtue of difficulties in patient recruitment.  
HD is a genetic neurodegenerative disorder that affects 2.71 per 100,000 persons 
worldwide.
4
 The pathology of HD is caused by an expansion in a trinucleotide CAG 
repeat in exon 1 of the Huntingtin gene, and the length of this repeat predicts disease 
onset in patients.
5,6
 Models predicting disease onset enable researchers to study HD 
before the start of overt disease features and by so doing the possibility of delivering 
novel therapies at disease onset.
7
 Whilst useful, we are still poor at modelling disease 
progression once the condition has started. We therefore sought to do this using our 
extensive database of 343 patients that we have followed longitudinally since 1995. We 
propose a model that tracks and predicts the natural progression of manifest HD based on 
the motor and functional components of the Unified Huntington's Disease Rating Scale 
(UHDRS), which are routinely used in HD clinics.  
We have found that patients with similar initial clinical profiles can have very different 
patterns of disease progression, which renders the use of conventional regression analysis 
(that estimates a common slope among groups of patients) inappropriate. In contrast, our 
novel approach enables researchers to predict disease progression of individual patients 
for the next two years, based on assessments from the past four clinical visits (with a 
minimum span over two years). We have interrogated the quality of our prediction by: a) 
extrapolating our equation to model the age of disease onset, b) testing it on a second 
patient dataset by loosening our filtering criteria, c) cross-validating with a repeated 
random sub-sampling approach, as well as d) holdout validating with the latest clinical 
assessment data from the same cohort of patients, which was unavailable at the time of 
our original modelling.  
We believe that our model will benefit clinicians and researchers in studying HD, 
especially for those developing potential disease-modifying therapies. Furthermore, our 
results enable researchers to reassess their existing data based on different profiles of 
patients’ predicted disease progression. Similar approach can also be adapted to model 
disease progression in other chronic disorders. 
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MATERIALS AND METHODS 
Patient recruitment and assessments  
Data was collected from participants who attended the HD clinic at the John van Geest 
Centre for Brain Repair, UK, between 1995- 2013, either as part of their routine clinical 
care, or through participation in related studies. This study was approved by the 
Cambridge University Hospital NHS Foundation Trust, in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki and its later amendments. All 
participants consented to their data being shared between research studies in an 
anonymised form. Motor and functional impairments were assessed using the UHDRS 
total motor score, functional assessment, and functional capacity scales, conducted by an 
experienced rater. The UHDRS total motor score ranges from 0 (no motor features 
detected) to a maximum score of 124. Manifest disease was defined as a total motor score 
≥5, as done previously.
8
 Demographic information was collected on patients including 
their CAG repeat size (where available), age and gender. 
 
Modelling methods  
A detailed description can be found in the supplementary file. In short, the initial data 
were filtered using the following three criteria: a) patients beyond the prodromal stage of 
disease with a ≥15 on their Generalised Index (GI) score (explained below) at their last 
clinical visit (up to 2012); b) patients with at least five clinical visits; and c) patients not 
showing a large negative validity score (table S1). The validity score was created to avoid 
potential complications from medications, based on an assumption that patients were not 
expected to improve with time, which is consistent with a recent finding.
9
 The validity of 
patients that showed improvement between two consecutive visits was penalised and 
their data is more prone to exclusion. Most patients were filtered out using criteria a) and 
b) above and at the end of the filtering process 68 patients were eligible for modelling 
(figure S2). 
Clinical data from the UHDRS was then transformed into GI scores, by deducting chorea 
and dystonia that has higher interrater variability,
10
 which in our experience could 
fluctuate over short periods of time, and did not correlate over time in our data (figure 
S1). The GI is normalised to 100, which represents an average of the motor and 
functional components of the UHDRS, and lies between 0 (no features) and 100 (all 
features). The optimum function to data from individual patients was fitted to best 
describe his/her GI progression, using linear (GI=B0+B1*Age), quadratic 
(GI=B0+B1*Age+B2*Age
2
), and exponential (GI=exp[B0+B1*Age]) models. The fitness 
of each model was quantitated as described in the supplementary file and previously.
11
 
We then searched the optimum coefficient for individual patients (B1 for linear, B2 for 
quadratic, both indicates the rate of disease progression) within a range (table S2), 
defined by the maximum and minimum value from the patient data (table S3). 
 
Prediction and model validation 
A detailed description can be found in the supplementary file. In short, the first N 
samples of each patient were used to classify and create a model that would describe the 
disease progression pattern for that patient (figure S3). The optimum coefficient was then 
generated as described above, while the other parameters were derived from the first n 
samples from that particular patient. Prediction is conducted in a moving-horizon sense; 
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as soon as the (n+1)
th 
sample is available, the above algorithm would re-classify and 
refine the model for that patient. Our predictions were validated using four different 
methods. Firstly, we extrapolated our model to predict the age of disease onset and 
compared that with a benchmark model built using large cohorts of patients.
5
 Secondly, 
we included data from the 31 new patients that were previously excluded for failing the 
validity score criteria. Thirdly, we took a repeated random sub-sampling approach by 
partitioning our 68 patients into training groups of 50 patients, with testing groups of 18 
patients. The procedure was repeated 40 times to eliminate selection bias. Finally, 23 out 
of our 58 patients had revisited our clinic in 2013, such that their latest clinical 
assessment data was unavailable at the time of modelling, and we could therefore use 
these data to validate the predicted versus actual GI score of disease progression. 
 
Data analysis 
Normality of data was verified using either the Kolmogorov-Smirnov (>50 samples) or 
the Shapiro-Wilk (≤50 samples) tests. For univariate and multivariate analyses we used 
parametric (e.g. ANOVA, mixed models ANOVA) and nonparametric methods 
(Friedman test, Kruskal-Wallis and Mann-Whitney test) depending on the distribution of 
residuals. For mixed model analyses of variance with multiple levels of repeated 
measures data transformation was performed to obtain normality if required (such as 
square root transformation). Univariate analyses were corrected for multiple comparisons 
(Bonferroni) in order to avoid type I statistical error. Matlab (version 7.9) were used for 
data modelling. SAS (version 9.1) and SPSS (version 21) were used for statistical 
analysis. 
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RESULTS 
The initial dataset contained a total number of 343 patients that we had followed since 
1995. The majority of the patient data failed to meet our filtering criteria were those 
having less than five clinical assessments, followed by those in the premanifest or 
prodromal stage.  
 
Disease progression from the final 58 patients that we were able to model, denoted by the 
GI, representing 85.3% of all eligible patients (n=68), are demonstrated (figure 1). 
Among these patients, 41 of them exhibited disease progression that could be described 
in a linear equation (GI = B0+B1*Age, left panels), while disease progression from the 
other 17 patients could be described in a quadratic equation (GI = B0+B1*Age+B2*Age
2
, 
right panels).  
 
 All 
n=343 
Filtered 
n=68 
Linear 
n=41 
Quadratic 
n=17 
Test 2 
n=31 
P 
Age at last visit 
(up to 2012)
a 52.2±1.0 55.1±1.5 55.7±1.9 53.7±3.3 55.7±2.1 0.267 
Male
 
(%)
b 
 
44.3 
(n=152) 
39.7 
(n=27) 
31.7 
(n=13) 
58.8 
(n=10) 
45.2 
(n=14) 
0.243 
CAG repeat
b 
43 (4) 44 (3) 44 (3) 44 (4) 43 (3) 0.018
c 
Years of follow-up
b 
5.1 (5.0) 6.0 (4.0) 6.6 (3.5) 6.0 (4.0) 5.7 (7.4) 0.009
c 
UHDRS motor score  
at last visit
b 17 (30) 36 (36)
d 
45 (34)
d
 30 (26)
e
 18 (17)
 
<0.001 
UHDRS functional 
score at last visit
b 28 (24) 12 (19)
d 
8.5 (17)
d
 12 (20)
e 
25 (10) <0.001 
Table 1 
a
Data from normally distributed samples was expressed as mean ±SEM; 
b
 data 
from nonparametric samples was expressed as median (interquartile range, IQR); 
c
Post-
hoc Mann Whitney test with Bonferroni correction revealed no true difference;
 d
Post-hoc 
analysis revealed significant differences (P<0.005, after Bonferroni adjustment) from the 
full cohort (n=343) and from the “test two” patients (relaxed validity score, n=31); 
e
Post-
hoc analysis revealed a tendency for a difference (P<0.05, after Bonferroni adjustment) 
between the full and included patients. 
 
We then compared the demographic information between different subgroups of patients, 
including data sets from a further 31 patients used in validation test two by relaxing the 
validity score. Clinically the subgroups could not be distinguished from one another in 
terms of the age of patients at their last clinical assessment (up to 2012, F4,493=1.306, 
P=0.267), gender distribution (H(4)=5.460, P=0.243), CAG repeat size (H(4)=11.953, 
P=0.018), and the average years of follow-up (H(4)=13.543, P=0.009) (table 1, post-hoc 
analysis with the latter two revealed no real difference). There were significant difference 
between patient subgroups in their UHDRS total motor (H(4)=55.216, P<0.001) and 
functional (H(4)=61.724, P<0.001) assessments as measured at the patient’s last clinical 
assessment (table 1). Post-hoc analysis revealed that the data from all patients eligible for 
modelling (n=68), as well as patients exhibiting a linear (n=41), or a quadratic disease 
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progression (n=17) were either significantly, or had a strong tendency to be more 
impaired in their UHDRS total motor and functional assessments, compared with the 
whole cohort (n=343) or those patients who failed the validity score requirement that 
were used for validation test two (n=31). Such a difference could be attributed to the 
presence of the validity score, which assumed gradual deterioration of HD features over 
time and was consistent with previous findings.
9,12
 However there were no inter-group 
differences between all patients eligible for modelling, and those demonstrating linear or 
quadratic disease progressions. Overall this indicates that patients sharing similar clinical 
profiles could exhibit very different patterns of disease progression. 
 
As there is no comparable model to predict HD progression, we started validating our 
approach by extrapolating our model to predict the age of disease onset. Comparison was 
made with the most popular existing model to predict disease onset, constructed using 
large, independent cohorts of patients.
5
 This helps deal with a major limitation of our 
model to predict disease progression, namely that we were only studying a relatively 
small cohort of patients from the east of England. To do this, data was selected from the 
41 patients with linear disease progression and the age of disease onset (T0) was defined 
as T0= . Our predictions were modelled by using an approach similar to Langbehn's, 
as well as by evaluating the maximum fitness criterion. Our resulting equation 
(T0=22.24+exp[9.844-0.156*CAG]), has very similar coefficients to Langbehn's 
(T0=21.54+exp[9.556-0.146*CAG]) (figure 2). This indicates that, despite the fact that 
our model was built using a smaller cohort, our approach is comparable to the benchmark 
disease onset model constructed using 2913 individuals. 
 
Our present modelling approach was based on the assumption that patients were not 
expected to improve over time, consistent with a recent observation.
9
 Therefore patients 
demonstrating large improvements over consecutive clinical assessments were penalised, 
making their data sets prone to exclusion from the filtering stage. We then revisited our 
assumption, by including data from 31 patients who were previously excluded due to 
them having an excessive validity score penalty. The results were analysed in terms of 
the percentage change between the predicted and actual GI score during the latest clinical 
visit, which ranged between <6 months, 6-12 months, 12-18 months, and 18-24 months 
from the last visit used for modelling. Furthermore, we sought to investigate whether the 
number of prior clinical assessments used for modelling affected the accuracy of 
prediction. The prior clinical assessments were grouped in categories ranging from 3 to 
≥8 prior visits, although our classification algorithm requires at least four prior clinical 
assessments to properly assign individual patients to their respective type of disease 
progression. By removing the validity score this represents the maximum level of 
prediction error we would expect from our modelling approach. 
 
We used mixed model analyses of variance to estimate fixed effects of time of prediction 
and number of prior assessments on prediction error. The mean prediction error was 8.4% 
(±5.3%). The multivariate analyses yielded a strong significant main effect of time of 
prediction (F3,73=6.97, P=0.0003), with no interaction between the two factors. In line 
with expectations that increasing time elapsed from the last clinical assessment would 
increase the prediction error, from an average of 5.9% (±4.2%) when predicting <6 
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month time period, to an average of 11.7% (±7.2%) at 18-24 month time prediction 
period (figure 3). Number of prior assessments used for the prediction did not yield a 
significant effect in the model (F5,17=1.70; P=0.19), despite of a tendency for an average 
decrease of 7% in prediction error when ≥8 prior visits were used as compared to 3. This 
was also in accordance with expectations. Our results indicates that the accuracy of 
prediction using our model is dependent on the time elapsed between last clinical 
assessments and is not affected by the amount of prior data used for that prediction. It has 
to be noted that the significant decrease in prediction accuracy of almost 6% in average, 
from the shortest to the longest prediction time period used in our prediction model when 
validity score were removed, is still relatively small as compared to the overall accuracy 
of 91% (±8%). 
 
We then attempted to cross-validate our approach by randomly partitioning the 68 
patients into “training” and “testing” groups, in order to avoid overfitting of our model. 
Patient data from a group of 50 random patients (training) were used to obtain the new 
optimum parameters (B1 for linear, B2 for quadratic), while the remaining 18 patients 
(testing) were used to evaluate the predictive power of these newly derived equations 
using the same statistical models as presented above. This process was repeated 40 times 
to avoid random selection bias. The mean level of error across the 40 random shuffling 
was 8.6% (±1.2%) between predicted vs. actual GI. When the predicted clinical 
assessment was conducted within 6 months of the last visit, the prediction error was on 
average 6.8% (±1%) and increased to only 12.4% (±2.8%) when the prediction time was 
increased to 18-24 month. Nevertheless, this effect was highly significant across the 40 
trials as the median P value was 0.0002 (IQR: 0.004) (figure. 4). In conformity with the 
previous test, the accuracy of prediction did not change when the number of prior visits 
was increased from 3 to ≥8, yielding a median P value of 0.38 (IQR: 0.6) across the 40 
random trials. Similarly there was no interaction between the two factors.  
 
We finally performed a holdout validation, by assessing our model against the latest 
clinical assessment data from patients who had come back to clinic in 2013 that were 
previously unavailable during model training. This holdout dataset consisted of 23 out of 
the original 58 patients we used to construct our model, with a total of 53 new clinical 
assessment data sets. Using a series of non-parametric analysis we could not observe any 
statistical differences between the predicted and the actual GI score in these patients 
(figure 5A). The median prediction error was 11.2 (IQR: 17.1). Using Spearman’s 
coefficient we found a highly significant correlation between the predicted and actual GI 
score ( =0.91, P<0.001, figure 5B). Similar to the previous validation tests, we then 
sought to analyse if there were any differences in the quality of prediction with the 
duration between the last (up to 2012) and present (2013) clinical assessments. However, 
we found no significant effect of time elapsed since last clinical assessment on the 
accuracy of the prediction (figure 5C). 
 
Although the size of CAG repeat length was not used to calculate the GI score, it is the 
major determinant of the age of disease onset, and we were therefore interested to 
examine if the number of CAG repeats affects the rate of disease progression (figure S4, 
table S4). For this, we used data from the 41 linearly progressing patients and calculated 
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the optimum B1 (rate) for each of the motor and functional components of individual 
patients (figure S5).  
 
CAG repeats Motor 
(actual) 
Functional 
(actual) 
Motor 
(normalised) 
Functional 
(normalised) 
40-44 2.79 7.63 0.79 0.94 
45-49 3.97 8.04 1.13 1.00 
>49 6.88 11.63 1.96 1.44 
Table 2 Mean values of B1 for motor and functional indices for different ranges of CAG 
repeat sizes. Both the actual and normalised values are reported. 
 
We divided patients into three subgroups according to their CAG repeat size, and noted 
that patients with longer CAG repeats had more rapid disease progression compared to 
patients with shorter CAG repeats (table 2). This is consistent with what had been 
reported previously.
13,14
 Furthermore, when the CAG repeat size increases, UHDRS total 
motor score deteriorates at a quicker rate as opposed to the functional components (figure 
6). We have also compared medications among different subgroups and did not observe 
any effects on disease progression profile (figure S6). 
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DISCUSSION 
In the present study we describe a novel modelling approach that can be used to track, as 
well as to predict, HD progression in manifest patients. The primary strength of our 
UHDRS-based model is that it is derived from measures routinely assessed in HD clinics 
worldwide, and its quality has been scrutinised using four validation methods. With at 
least four prior clinical assessments over a minimum span of two years, we can faithfully 
predict HD progression for individual patients over the next two years. Patients with 
similar clinical profiles (age, CAG repeat length, UHDRS) can also exhibit very different 
profiles of disease progression, and we can model this along with providing evidence that 
patients with longer CAG repeat size have a quicker rate of disease progression. Further 
studies will however be required to determine the underlying causes for the latter two 
observations. 
Over the past few years much effort has gone into uncovering potential biomarkers to 
track HD progression. For example, the level of striatal brain-derived neurotrophic factor 
(BDNF) was shown to be substantially reduced in HD patients.
15
 Therefore the level of 
plasma BDNF in 398 HD patients was studied, before concluding that neither the serum 
level of BDNF protein nor mRNA could be reliably matched to stages of HD severity.
16
 
On the other hand, Weiss and colleagues
17
  have demonstrated that the level of mutant 
Huntingtin (mtHtt) aggregation in the peripheral immune cells was significantly 
increased, when comparing premanifest to manifest HD patients. In addition, there was 
also a significant correlation between disease burden scores of individual patients with 
the level of mtHtt aggregation in the peripheral immune cells
17
, although there was 
considerable intra-individual variability on the level of aggregation between samples 
from the same participant. Furthermore, Tabrizi and colleagues
18
 have also systemically 
evaluated the utility of a range of biomarkers in large cohorts of patients (TRACK-HD). 
They demonstrated that the rate of changes in the motor and functional components of the 
UHDRS were associated with disease progression.
18
 However, all these studies took a 
categorical approach by grouping patients in accordance to their disease stages for 
analysis. In contrast, patients in our study were tracked longitudinally as disease 
progressed and deteriorated, while the degree of GI changes was analysed on an 
individual basis. We believe that such an approach could better represent the 
heterogeneity of disease progression in individual patients, as we have observed in our 
cohort. Similar longitudinal strategies have also been employed in two very recent 
reports.
7,9
 In the Dorsey study both the motor and functional components of UHDRS, as 
well as several cognitive measures, were found to consistently deteriorate in HD patients 
followed for three years.
9
 In the Tang study, the authors used functional imaging tools to 
demonstrate their potential as biomarkers to track preclinical HD, as the metabolic 
activity of the neural network was linearly associated with disease progression in 
premanifest HD patients.
7
 
There are though limitations to our study. Most notably all our patients were recruited 
from a single centre, and their generalizability remains to be demonstrated. We have 
however demonstrated that the age of disease onset derived from our cohort was very 
similar to that described by an international, multi-centre study using larger cohorts of 
patients.
5
 Furthermore, our approach enables disease modelling and progression to be 
analysed on an individual basis, while the optimum coefficients can be re-defined for 
specific cohorts of patients. Such flexibility could facilitate the translation of our 
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approach to other research centres. Another problem is that all patients in our study were 
examined by a single clinician that removes issues to do with interrater variability, 
although it had previously been shown that there is a high correlation coefficient for the 
UHDRS total motor score between clinicians.
10
 Finally to address the possibility of 
overfitting our model, we have cross-validated our modelling and prediction using a 
repeated random sub-sampling approach, as well as performing a holdout validation 
using data from the patients’ latest clinical assessments, which took place between 2013 
and were unavailable at the time of model training. 
In conclusion, using HD as an example we have developed a model to track the natural 
history of disease progression in manifest patients. With data from the previous four 
clinical visits based on the conventional UHDRS assessment, we can predict disease 
progression that is statistically not different from the actual progression over the next 24 
months. We believe that our model will be an extremely valuable tool, both in terms of 
enabling researchers to reassess their existing data according to patients’ different types 
of predicted disease progression, as well as facilitating the development of novel disease 
modifying therapies in the future. We also believe that similar approaches can be adapted 
to model clinical progression of other chronic neurodegenerative disorders. 
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FIGURE LEGENDS 
 
Figure 1 Spaghetti plot of disease progression (top panels) and the best-fit line (bottom 
panels) of individual HD patients whose disease progression can be described in a linear 
(n=41, left panels) or quadratic (n=17, right panels) fashion. 
 
Figure 2 Comparison of the mean age of disease onset for CAG repeat lengths 40–65, 
betwee  that estimated by the Langbehn et al.,
5
 or from HD patients in our cohort 
exhibiting a linear disease progression (n=41). 
 
Figure 3 The effect of factor time of prediction from the last visit used for modelling 
(four categories) and factor number of data sets from prior clinical visits used for 
modelling (six categories) on prediction error after removing the validation index. 
Vertical bars indicate mean prediction error calculated as percentage change between the 
predicted and actual general index score during the latest clinical visit. Whiskers indicate 
standard error. Post-hoc differences are indicated for factor time of prediction from the 
last visit which yielded a significant main effect. Numbers in the bottom of the vertical 
bars indicate number of data sets (n) within each category. Data was subjected to square 
root transformation prior to analysis. * p<0.05, ** p<0.01, and *** p<0.001, respectively. 
 
Figure 4 The effect of factor time of prediction from the last visit used for modelling 
(four categories) and factor number of data sets from prior clinical visits used for 
modelling (six categories) across 40 random trials during which participants were 
randomly reassigned into either ‘training’ or ‘testing’ groups. Vertical bars indicate mean 
prediction error across the 40 trials calculated as percentage change between the 
predicted and actual GI score during the latest clinical visit. Whiskers indicate mean 
standard error across the 40 trials. Mean Post-hoc differences are indicated for factor time 
of prediction from the last visit which yielded a mean significant main effect. Numbers in 
the bottom of the vertical bars indicate number of data sets (n) within each category. * 
p<0.05, ** p<0.01, and *** p<0.001, respectively. 
 
Figure 5 The association between the actual and predicted GI in the holdout validation. 
(A) The overall mean and standard error of actual and predicted general index. (B) The 
correlation between predicted and general index (Spearman Rho). Calculated 
(continuous) and ideal (dashed) regression lines are indicated. (C) The difference 
between the actual (A) and predicted (P) general index overall and for each participant 
and each category of time elapsed since the last clinical assessment (four categories). (D) 
The ratio between the predicted versus actual GI for all and for each category of time 
elapsed since the last clinical assessment. 
 
Figure 6 Optimum values for B1 (rate of disease progression) versus CAG repeats for 
patients exhibiting linear disease progression (n=41) for motor and functional indices. 
Values of B1 for each index are normalised to the mean B1 value. 
 
Page 14 of 31
http://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
  
 
 
Spaghetti plot of disease progression (top panels) and the best-fit line (bottom panels) of individual HD 
patients whose disease progression can be described in a linear (n=41, left panels) or quadratic (n=17, right 
panels) fashion.  
98x77mm (300 x 300 DPI)  
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Figure 2 Comparison of the mean age of disease onset for CAG repeat lengths 40–65, between that 
estimated by the Langbehn et al.5, or from HD patients in our cohort exhibiting a linear disease progression 
(n=41).  
50x40mm (300 x 300 DPI)  
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The effect of factor time of prediction from the last visit used for modelling (four categories) and factor 
number of data sets from prior clinical visits used for modelling (six categories) on prediction error after 
removing the validation index. Vertical bars indicate mean prediction error calculated as percentage change 
between the predicted and actual general index score during the latest clinical visit. Whiskers indicate 
standard error. Post-hoc differences are indicated for factor time of prediction from the last visit which 
yielded a significant main effect. Numbers in the bottom of the vertical bars indicate number of data sets (n) 
within each category. Data was subjected to square root transformation prior to analysis. * p<0.05, ** 
p<0.01, and *** p<0.001, respectively.  
51x40mm (300 x 300 DPI)  
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The effect of factor time of prediction from the last visit used for modelling (four categories) and factor 
number of data sets from prior clinical visits used for modelling (six categories) across 40 random trials 
during which participants were randomly reassigned into either ‘training’ or ‘testing’ groups. Vertical bars 
indicate mean prediction error across the 40 trials calculated as percentage change between the predicted 
and actual GI score during the latest clinical visit. Whiskers indicate mean standard error across the 40 
trials. Mean Post-hoc differences are indicated for factor time of prediction from the last visit which yielded a 
mean significant main effect. Numbers in the bottom of the vertical bars indicate number of data sets (n) 
within each category. * p<0.05, ** p<0.01, and *** p<0.001, respectively.  
51x42mm (300 x 300 DPI)  
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The association between the actual and predicted GI in the holdout validation. (A) The overall mean and 
standard error of actual and predicted general index. (B) The correlation between predicted and general 
index (Spearman Rho). Calculated (continuous) and ideal (dashed) regression lines are indicated. (C) The 
difference between the actual (A) and predicted (P) general index overall and for each participant and each 
category of time elapsed since the last clinical assessment (four categories). (D) The ratio between the 
predicted versus actual GI for all and for each category of time elapsed since the last clinical assessment.  
131x41mm (300 x 300 DPI)  
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Optimum values for B1 (rate of disease progression) versus CAG repeats for patients exhibiting linear 
disease progression (n=41) for motor and functional indices. Values of B1 for each index are normalised to 
the mean B1 value.  
51x40mm (300 x 300 DPI)  
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Supplementary material: 
1. Introduction  
This supplemental material contains the details of the mathematical tools used for 
analysis of the data. It also explains the choice of model classes and validation criteria. It 
is divided into two parts. The first part discusses the data available and the filtering and 
normalisation criteria, while the second part focuses on the mathematical modelling of 
that data. Model validations can be found in the results section of the main manuscript. 
 
2. Data management  
For this work we used data from regular patient visits collected by Prof. Barker from 
1995 until 2013 for 343 patients. For every visit of a patient, it contains all the scores that 
lead to the total Unified Huntington’s Disease Rating Scale (UHDRS), plus patient ID, 
age, gender, education years, left or right hand sided, CAG minor and major. 
 
2.1 Filtering the data - Mapping to a feature vector  
To increase the robustness and reliability for training the model, some of these 
parameters, such as chorea and dystonia, were removed from modelling since to our 
experience they can show great variations in a relatively short time as well as having high 
inter-rater variability. Furthermore, in our data set there was no significant correlation 
between either the UHDRS total maximal chorea score (r=0.008, P=0.713) or the total 
maximal dystonia score (r=-0.008, P=0.718) over time (figure S1). 
 
Some of the sample sets were incomplete. Hence, we could either interpolate the missing 
data (by using the rest of the data to estimate the missing ones) or just not use these data. 
The latter was chosen, as the interpolation method could introduce undesirable noise. 
From the resulting data, each patient visit was reduced to a feature vector containing the 
information required for our analysis. The feature vector contained the following 
information: 
 
Patient's ID.  
Patient's age at the time the sample was taken.  
The length of their CAG repeats.  
The percentage of symptoms in the UHDRS motor scores at that time.  
The percentage of symptoms in the UHDRS functional scores at that time.  
The General Index (GI), which was the average of motor and functional indices.  
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This feature vector allowed the reduction of the dataset vector, while keeping all the 
information required for classification and prediction. 
 
2.2 Filtering out not suitable patients  
The next step was to choose an appropriate set of patients for training the model. The 
following three criteria were introduced to filter out patients: 
The first criterion was to use patients that were beyond the prodromal stage of the 
disease. Quantitatively, a patient must have at least 15% of all the features at his most 
recent assessment to be considered for modelling. The criterion was introduced after 
noticing that at the prodromal stage of the disease there was not a clear trend in the data. 
This is probably caused by factors independent of the disease that dominate the test 
results, such as ageing and noise (e.g. quantisation of data scores).  
Secondly, in order to maximise the validity of the model, patients were required to have a 
relatively large number of assessments. To make the mathematical modelling problem 
well-posed, it is often required that the number of samples is much larger than that of 
parameters in the model. However, increasing the required number of assessments to 
more than five resulted in having too few patients for modelling.  
 
 
Difference in GI between two consecutive samples (%) Change in validity score 
≥ 5 +5 
0 - 5 +1 
-3 - 0 -5 
≤ -3 -10 
Table S1 Dependence of validity scores on the change of GI between consecutive 
samples. 
 
Thirdly, a validity score was created based on the assumption that a patient was not 
expected to improve with time and was penalising the validity of patients that showed 
improvements. Due to a somewhat random behaviour, patients with low validity were 
harder to model and, hence, were not used for modelling. The validity score was 
calculated as shown in table S1. For each visit, a patient's validity score was updated 
according to the difference between his current and previous GI scores. Patients with a 
validity score of less than -8 were filtered out. This boundary value was selected by 
observing the progression of the disease in several patients and comparing their validity 
score. Patients with scores below that value could not be used for modelling.  
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Figure S2 Schematic of the filtering procedure to obtain suitable for modelling patients. 
 
 
At the end of the filtering stage there were 68 patients from the initial 343 that could be 
used for modelling. Note that the major reason for excluding patients was because of 
them not having enough assessments. The data filtering procedure is summarised in 
figure S2. 
 
3. Modelling, classification and prediction  
This section is dedicated to the modelling aspects of the project. It is divided into two 
subsections that provide the necessary details to repeat our analysis. The first part 
describes how the data was used for the creation of a model. The second part explains 
different methods to validate the models. 
  
3.1 Modelling procedure  
3.1.1 Fitness function  
To understand the quality of a model, we need a way to quantify its performance. 
Adopted from standard system identification textbooks
1
, in this paper we use the 
following measure of how well a curve fits the data 
 
                                             fitness = 1 -     (3.1) 
 
where  is the value of the index as predicted from the model, yk is the real value and  
is the mean value of all the data we have in that sample. Note that we obtain 100% fitness 
for a perfect fit. In a sense, it quantifies how well a certain model fits the data compared 
with a constant model that always equals the mean of these data. In this paper, we 
considered that models with a fitness higher than 70% described reasonably well the data. 
 
3.1.2 Fitting the optimum function for each patient  
To understand the classes required for modelling, we started by modelling individual 
patients, instead of searching for one of a few models that explained all the patients. 
Hence, we isolated each patient's data and tried to find a model that would best describe 
the patient’s GI growth. The candidate models were linear, quadratic and exponential and 
implemented as follows: 
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1. The linear model assumed the General index (GI) was proportional to age. This 
was implemented using the following equation  
 
GI = B0+B1*Age    (3.2) 
  
where, for each patient, the values for B0 and B1 minimum mean squared error and 
maximum fitness. Rewriting the above equation as Ax = B, with appropriate choices for 
A, B and the unknowns x, the problem reduces to a standard least squares minimisation 
problem which has a solution given by 
 
x = (A
T
 A)
-1
  (A
T
 B)    (3.3) 
 
In our case, x is a vector containing the optimum values for B0 and B1, A is an N x 2 
matrix, where N is the amount of samples obtained from a specific patient. The left 
column of A contains only the number 1 while the right column contains the patient's age 
at the time when the sample was taken. Matrix B is of size N x 1 and contains the GI 
index's value for each sample. 
 
2. The quadratic model assumed that the GI index varied with the square of the age 
and is given by the following equation  
 
GI=B0+B1*Age+B2*Age
2
   (3.4) 
 
As in the linear model's case, we estimated the minimum mean squared error values for 
B0, B1, and B2 using equation 3.3. In this case, x contained these three values. 
 
3. Finally, the exponential model assumed that the GI index depended on the 
exponential of the patient's age and is given by  
 
GI=exp[B0+B1*Age]    (3.5) 
 
Again, the optimum coefficients were obtained from equation 3.3. 
 
Patient 
ID 
Fitness Optimum parameters 
Linear 
model 
Quadratic 
model 
Exponential 
model 
Linear Quadratic Exponential 
B1 B0 B2 B1 B0 B1 B0 
4 0.948 0.960 0.897 8.65 -394 -0.62 74 -2102 0.155 0.0168 
15 0.956 0.975 0.970 6.76 -492 0.35 -50 1790 0.139 0.0007 
16 0.973 0.983 0.981 5.41 -319 0.24 -27 858 0.134 0.0053 
51 0.941 0.976 0.972 7.25 -314 0.63 -57 1323 0.130 0.0691 
58 0.798 0.798 0.755 7.45 -410 -0.05 14 -599 0.167 0.0015 
62 0.897 0.914 0.841 5.99 -360 -1.11 147 4819 0.344 0.0000 
79 0.869 0.946 0.780 7.61 -481 -2.90 395 -13451 0.297 0.0000 
Table S2 Table with fitness and optimum coefficients for the three candidate models for 
seven patients. 
 
Page 24 of 31
http://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Hence, for each patient we obtained the fitness for each of the three models together with 
the optimum coefficients that produced it. Table S2 shows a sample of seven out of the 
68 patients. 
 
 
3.1.3 Classification of patients to model classes  
After obtaining optimum values for the parameters of the three candidate models, the 
fitness of each model was calculated for every patient, using equation 3.1. We then 
observed the following remarks: 
 
 The fitness of quadratic models was always better than linear ones. This was 
expected, since the extra parameter made the quadratic model more flexible.  
 
 The fitness of the exponential model was always worse than the quadratic. Hence, 
we did not consider this model any further.  
 
 
 
Figure S3 Flow chart of the classification procedure. 
 
The following criteria were used to choose which model (linear, quadratic or others) was 
more appropriate for each patient. The first step was to check if either model could 
capture the data of a particular patient. If not, the patient was classified as “Others”. It 
was decided that the acceptable fitness for this was 70%. Hence, a patient with fitness 
less than 70% on either model was classified as “Others”. For patients with fitness higher 
than 70% on at least one model, the second step was to choose the model that best 
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describes the patient. Since quadratic fitness was always better than linear, we decided 
that quadratic class was chosen only if its fitness was at least 4% greater than the linear 
model's fitness. This is to avoid the likely overfitting, i.e. if the difference was lower than 
4%, the extra fitness did not justify the extra model complexity. Hence, in this case, the 
linear model was selected. The third and last step was to address an issue with quadratic 
models. In some patients with a high fitness in a quadratic class but a negative B2 (recall 
that the quadratic class was given by GI=B0+B1*Age+B2*Age
2
). This predicted that the 
disease would progress at a slower rate for later stages and eventually the patient would 
improve. Hence, it would most likely result in bad predictions. Therefore, patients were 
excluded rom the Quadratic class when they had a negative B2. The classification 
algorithm is demonstrated schematically in figure S3. 
 
3.1.4  Aggregate optimal coefficients 
Class Linear Quadratic 
Parameter B1 B0 B2 B1 B0 
Minimum 2.67 -588 0.21 -732 132 
Maximum 12.95 -72 6.62 -10 2030 
 
Table S3 Range of coefficients for each patient's optimum equation. 
 
Linear model: for the linear models, the previous part showed that its coefficients 
exhibited high variability (see table S3 for the range of these values). Hence, an aggregate 
single model resulted in a poor description of the whole linear class so we decided to find 
two subclasses for the linear model class. In the linear models, the parameter B0 is very 
dependent on each patient and is related to the age of onset of the disease. Hence, this 
parameter needs to be calculated for each patient. The most important parameter is, in 
fact, B1 since this captures the rate at which the disease progresses. Hence, this is the 
parameter that aggregated in two subgroups. For a given value of B1, we calculated the 
optimum value of B0 using a similar expression to 3.3, where A is a N-sized vector of 
ones (N is the number of samples for each patient) and B is an N-sized vector consisting 
of the GI index's value minus the value of B1 times the age when the sample was taken. 
The value of x gave the optimum value for B0 for that patient. 
We used a greedy algorithm that computed all possible combinations to simultaneously 
evaluate two linear models with different values for B1 between the range 2.67 to 12.95 
(table S3). This resulted in the globally optimum solution for two linear subclasses. The 
solution was one class with B1 = 6.86, fitting 29 patients well with at least 70% fitness, 
and a second class with B1 = 3.30, fitting well 11 patients. Hence, the linear class was 
divided into two subclasses: Linear A with B1 = 6.86 and Linear B with B1 = 3.30. 
Patients were classified into either Linear A or Linear B, by choosing the corresponding 
highest fitness (always required being above 70%). The dividing point between both 
Linear classes was 4.92, which was chosen to maximise the margin between the two 
classes. It was calculated as the average of the maximum B1 coefficient between the 
patients of the Linear B class and the minimum B1 coefficient between the patients in 
Linear A. We also tried dividing the Linear group into more than two classes. However, 
although the overall fitness increased, the data was over fitted and, in some 
circumstances, resulted in poor predictions. 
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Quadratic model: as above, the most important parameter for the quadratic model is B2, 
which ranges between 0.21 to 6.62 (table S3). The other two parameters, B0 and B1, were 
very dependent on the individual patient. For each value of B2, to obtain the optimum 
coefficients B0 and B1, equation 3.3 was again used with x having the values of B0 and B1, 
vector A containing a column of ones and a column of ages and vector B containing the 
GI index values minus B2 times the age squared. We then optimised over B2, with the best 
value of 0.64, and giving at least 70% fitness for 16 out of 17 quadratic patients.  
 
3.2 Prediction stage  
With models in place, the next step was to check how good the models could predict 
future data. To make a prediction, the first N samples of each patient were used to 
classify the patient and to create a model that would describe the progression of the 
disease. This model was used to make predictions for up to two years (if the amount of 
samples allowed it). The metric used to evaluate the results was the standard error 
between our predicted values and the real ones. This section explains how to classify a 
patient given a number of visits and the criteria that make a prediction trustworthy. 
 
3.2.1 Classification  
Before making any predictions, we first need to classify each patient in one of the groups 
Linear A, Linear B, Quadratic or Others using only the first N samples. The classification 
method was similar to the one in the initial classification (when all the data was 
available). To differentiate patients between Linear A and Linear B classes, patients were 
in Linear A if their optimum coefficient for B1 was greater than 4.92 and Linear B 
otherwise. 
An equation for each patient was then created as follows. Depending on the model class 
of the patient determined from the classification stage, the most significant coefficient 
was fixed to one of the three values: B1 = 6.86 for Linear A, B1 = 3.30 for Linear B and 
B2 = 0.64 for Quadratic group (with B1 as defined in quation 3.2 and B2 as in equation 
3.4). The remaining coefficients were found using the method explained in section 3.1.2. 
  
3.2.2 Developing and evaluating the predictions  
The method was evaluated by calculating the proportion of correctly classified patients 
when only their first N data points were used. We made predictions on all patients except 
those where: 
 
 Only N points were available, since in this case no future data was available to 
evaluate the prediction,  
 
 And the patient was classified in the group Others, since in this case the 
prediction could not be trusted.  
 
Predictions were made for each patient for up to four future time steps. Each time step 
represented a period of six months (hence, the fourth step prediction was for 18 - 24 
months). 
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4. Additional Findings from our Analysis  
4.1 Rate of change for Linear class with CAG length.  
 
Figure S4 Optimum values for B1 versus CAG repeats for the 41 patients of the Linear 
class. 
 
After obtaining the optimum coefficients for each patient (as explained in section 3.1.2) 
and classifying our patients (section 3.1.3), we attempted to create an equation that would 
predict B1 value's for the linear model using only the length of patient's CAG repeats. The 
values for optimum B1 for each patient classified in the Linear class (either Linear A or 
Linear B) with their corresponding lengths of CAG repeats are shown on figure S4. From 
this figure, given the variability of B1 for given CAG repeats, it can be deduced that a 
prediction of B1 based on CAG repeats alone is not possible. 
 
CAG repeats Linear (n=41) Linear A (n=29) Linear B (n=11) 
40-44 6.05 7.44 3.38 
45-49 6.74 7.87 3.93 
>49 10.28 10.28 No data 
Table S4 Mean values of B1 for certain ranges of CAG repeats for classes Linear, Linear 
A and Linear B. 
 
The correlation of B1 values with CAG repeats was found to be 0.42 using Spearman's 
test. The P value to reject the hypothesis that B1 and CAG repeats are correlated was less 
than 1%. Hence, from this analysis, it can be concluded that CAG repeats is one factor 
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that affects the value of B1 but it is not the only one. As table S5 suggests, a higher value 
of B1 is expected when a larger CAG repeats' length is encountered. 
 
 
Figure S5 Optimum values for B1 versus CAG repeats for the 41 patients in the Linear 
class for Motor and Functional indices. 
 
4.2 Analysis of motor and functional symptoms  
Thus far, only the overall GI was considered, obtained as the mean of motor and 
functional indices. Next we investigated how the rate of change of progression of the 
disease differed between the two indices. For this, we used only patients in the Linear 
group and calculated the best fit line for each index and patient. The method to obtain the 
coefficients of this line was described in section 3.1.2. The values of B0 and B1 that 
minimised the mean square error between the data and equation GI = B0+B1*Age were 
then calculated for each index. The optimum coefficient was again B1, which described 
the rate of increase of each index (motor or functional). The results are summarised in 
figure S5, which shows that, in general, the optimum B1 for functional indices were 
larger than the corresponding ones for motor index. The mean value of B1 for motor 
index was 3.62 and for functional index 8.16. We then investigated the following: 
 
 Whether the expected value of B1 increases with an increase in the CAG repeats.  
 Whether the relative increase of B1 between low and high CAG repeats for the  
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To ease the comparison, the values of B1 for the two indices were normalised by their 
averages. This is shown on figure 6 of the main manuscript, where both indices have 
means of 1.0. To get the trends for the two indices, we obtained the average value of B1 
for each index in different ranges of CAG repeats. The results are shown in table 2 of the 
main manuscript. This table reveals that the expected value of B1 for each index increases 
with the length of CAG repeats. Columns four and five, obtained by dividing columns 
two and three by the average of all values for each index, show that the expected value of 
the motor index for B1 becomes almost twice the average when a longer CAG repeat is 
encountered. If this value is compared with the corresponding one for low CAG lengths, 
the ratio becomes almost 250% (1.96 over 0.79). For the functional index, that ratio is 
close to 150%. From these results, we conclude that an increase in CAG repeats has a 
much stronger effect in motor progression than in functional deterioration. 
 
4.3 No difference of medications between patient subgroups 
In order to compare whether there was any difference in medications between subgroups 
of patients (Table 1), the number of times each patient was taking medications was 
divided by his/her number of visits. Hence for each patient, a value between 0 and 1 for 
each medication was obtained. This value was the proportion of visits that the patient 
received that particular medication. The metric used for each medication was the average 
of this value for all patients. We could not observe any difference between medications 
taken among different subgroups of patients (figure S6). Furthermore we did not find any 
evidence how medications taken affected the rate of disease progression. 
 
 
Figure S6 Top 10 medications being taken by patients among different subgroups. 
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